Publications found:
97,050
Sort by:
2012 U.S. Input & Output Outlook
US$ 199.00
The 2012 U.S. Input & Output Outlook report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2012 current es...
July 2012
264 pages
Cempra: “GAIN from Drugs for Bad Bugs”
US$ 140.00
Drug resistance is a growing concern worldwide and Cempra (CEMP) is one of our lead recommendations ... offer an attractive investment opportunity in this therapy class. CEMP’s lead drug, 1. Solithromycin (CEM-101, PhIII, CABP; PhII cUTI) ... released on 2nd July, 2012 on CEMP titled “GAIN from Drugs for Bad Bugs”
July 2012
9 pages
US Cardiac Device Market Analysis
US$ 1,000.00
The higher prevalence of cardiovascular diseases has become a cause of concern for the US healthcare authorities as mortalities tend to rise and economic burden keep increasing. It is estimated that t...
July 2012
75 pages
US Clinical Laboratory Testing Market Assessment
US$ 1,000.00
The US represents an attractive destination for healthcare services’ market segments, especially clinical lab testing, which has evolved as a major source of decisive factor for healthcare professiona...
July 2012
45 pages
Onyx Pharma – Kyprolis to Accelerate Growth
US$ 140.00
... events – cardiovascular toxicities and deaths associated with Kyprolis as expected. ONXX has finally succeeded in ... Nexavar (L, RCC, HCC, partnered with Bayer), Kyprolis, and Regorafenib (R, oral multi-kinase inhibitor, GIST ... on Jun 21, 2012 on Onyx Pharma titled “Onyx Pharma - Kyprolis to Accelerate Growth”
June 2012
4 pages
Celgene: Long-Term Prospects Intact but Competition Emerging!
US$ 140.00
... flat growth of Revlimid (L, RRMM, MDS), reported in its 1Q12, we expect Celgene (CELG) to meet its FY12 guidance (Total rev.: $5.4-$5.6b and EPS ... , please read our report, released on 12th June on CELG, titled “Long-Term Prospects Intact but Competition Emerging!”
June 2012
3 pages
VERTEX PHARMA - Time to Book Profits
US$ 140.00
Vertex (VRTX) has evolved from an innovator to a profitable Biotech but at the ... detail, please read our report released on 11th June, 2012 on Vertex titled “Time to Book Profits….!”
June 2012
4 pages
Prioritizing Generic Drug development pipeline – The top Fifty Opportunities
US$ 5,000.00
... crucial aspects of growth strategy for a generic company or an Active Pharmaceutical Ingredient manufacturing ... recently approved or are in late stage development / Filed but with significantly success probability ... / therapeutic value compared to marketed drugs Anticipated competition in the therapy and ...
June 2012
100 pages